Clinical Trials Logo

Clinical Trial Summary

This is a study aiming to assess the efficacy and safety of Keluo Xin capsule in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR). Two-thirds of participates will receive Keluo Xin capsules while other one third will receive placebo.


Clinical Trial Description

This study composes two parts. The first is a 24-week period during which subjects receive designed treatment regimen; after that, subjects will be informed again for the next 24-week regimen (extention phase) and can choose whether or not to participate in the treatment (with the same regimen in the first period) voluntarily. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03258242
Study type Interventional
Source Chengdu Kanghong Pharmaceutical Co., Ltd.
Contact Yanping Song, Professor
Phone +86-27-50772574
Email songyanping@medmail.com.cn
Status Not yet recruiting
Phase Phase 2
Start date August 31, 2017
Completion date February 28, 2020